{
  "success": true,
  "pagesUsed": [
    0,
    1,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    20,
    21,
    22,
    23,
    24,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Upadacitinib",
        "type": {
          "id": "1a579f1f-4096-4258-9a20-d803a6c6c3a6",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "8002e195-bfb5-4c56-96a2-cd94d4b8ef4c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Methotrexate (MTX)",
        "type": {
          "id": "63d955db-741a-4ff4-870c-78764be9013c",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "88f6b495-1fbd-4684-804a-f43f115cd9f8",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Placebo for Upadacitinib",
        "type": {
          "id": "b523eeec-4d14-46c5-a9d5-a77e9fe47c83",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "824a98d4-36e4-40e4-9abd-de64a511b80f",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Placebo for MTX",
        "type": {
          "id": "50478530-0904-4045-9d59-5c91583429d6",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "7aef0646-7588-43c1-a7cc-d508730946bf",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for methotrexate to maintain blinding.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Folic acid",
        "type": {
          "id": "a8bcb813-eea0-409b-b94d-9c05c3581511",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "a4a2f4a0-e25a-4988-81eb-cdc36f517a87",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "id": "int_6",
        "name": "Corticosteroids",
        "type": {
          "id": "2181f2ab-d165-4a0d-b90c-cd921b506e13",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "de66dc1f-a882-4478-90d0-1a362d5be285",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "id": "int_7",
        "name": "NSAIDs",
        "type": {
          "id": "5d404334-d548-44c8-beb2-10b0f744b8ad",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "fe30f527-6dc8-4924-bce6-062189f05631",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "id": "int_8",
        "name": "Acetaminophen",
        "type": {
          "id": "317cae36-236e-44a9-aae9-3679ef124482",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "5da0c896-ad30-4c7f-9687-96512968cc40",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted for pain management."
      },
      {
        "id": "int_9",
        "name": "csDMARDs",
        "type": {
          "id": "74f9184d-bb3d-4b27-ba2a-541ca35532ca",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "8958b90c-4e78-40fc-959c-8bbd8467b81e",
          "code": "C54125",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Rescue Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "id": "int_10",
        "name": "Strong CYP3A inhibitors/inducers",
        "type": {
          "id": "a2166054-63a6-4864-9e11-4f9d47ce3815",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "1ccf44d4-e6d5-4596-87e1-61fe96bec1af",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "id": "int_11",
        "name": "High-potency opiates",
        "type": {
          "id": "75352667-2ccb-4bfa-b2b4-00d1f3e2d7cf",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "93c13b90-0d24-42bb-af20-02e926729bf0",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Upadacitinib tablet",
        "administrableDoseForm": {
          "id": "0fd9f80a-8710-43cb-a15e-1009ea7416cd",
          "code": "C42998",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Tablet",
          "standardCode": {
            "id": "294e8037-3047-43b3-88bc-cef4268dc76e",
            "code": "C42998",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Tablet",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "633c1eda-eb8c-41ef-b580-df00018098a3",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "15 mg, 30 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "AbbVie"
      },
      {
        "id": "prod_2",
        "name": "Methotrexate capsule",
        "administrableDoseForm": {
          "id": "4e7afcef-7357-45ee-999b-e55e515f3a35",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "62fecdd2-30d5-4c52-81f5-8703f21a49dd",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "5a34e72f-25d0-4c89-9ea7-a6b9ce30b7be",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Upadacitinib 15 mg QD",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Up to 260 weeks"
      },
      {
        "id": "admin_2",
        "name": "Upadacitinib 30 mg QD",
        "instanceType": "Administration",
        "dose": "30 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "id": "admin_3",
        "name": "Methotrexate weekly",
        "instanceType": "Administration",
        "dose": "7.5 mg to 25 mg",
        "doseFrequency": "once weekly",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "14 weeks (Period 1)"
      },
      {
        "id": "admin_4",
        "name": "Upadacitinib 15 mg Open-Label",
        "instanceType": "Administration",
        "dose": "15 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Upadacitinib",
        "instanceType": "Substance",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "id": "sub_2",
        "name": "Methotrexate",
        "instanceType": "Substance",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 11,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Upadacitinib",
        "role": "Investigational Product",
        "description": "Selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis."
      },
      {
        "name": "Methotrexate (MTX)",
        "role": "Comparator",
        "description": "Active comparator for Period 1; background therapy or discontinued in Period 2."
      },
      {
        "name": "Placebo for Upadacitinib",
        "role": "Placebo",
        "description": "Matching placebo tablet for upadacitinib to maintain blinding."
      },
      {
        "name": "Placebo for MTX",
        "role": "Placebo",
        "description": "Matching placebo capsules for methotrexate to maintain blinding."
      },
      {
        "name": "Folic acid",
        "role": "Background Therapy",
        "description": "Required dietary supplement for subjects taking MTX."
      },
      {
        "name": "Corticosteroids",
        "role": "Concomitant Medication",
        "description": "Oral corticosteroids (≤ 10 mg/day prednisone equivalent) permitted if stable; rescue use allowed after Week 26."
      },
      {
        "name": "NSAIDs",
        "role": "Concomitant Medication",
        "description": "Permitted if dose is stable for at least 1 week prior to first dose."
      },
      {
        "name": "Acetaminophen",
        "role": "Concomitant Medication",
        "description": "Permitted for pain management."
      },
      {
        "name": "csDMARDs",
        "role": "Rescue Medication",
        "description": "Initiation or adjustment allowed starting at Week 26 for subjects not achieving LDA."
      },
      {
        "name": "Strong CYP3A inhibitors/inducers",
        "role": "Concomitant Medication",
        "description": "Prohibited from Screening through the end of the study."
      },
      {
        "name": "High-potency opiates",
        "role": "Concomitant Medication",
        "description": "Prohibited during the study; must be washed out 1 week prior to first dose."
      }
    ],
    "products": [
      {
        "name": "Upadacitinib tablet",
        "doseForm": "Tablet",
        "strength": "15 mg, 30 mg",
        "manufacturer": "AbbVie"
      },
      {
        "name": "Methotrexate capsule",
        "doseForm": "Capsule",
        "strength": "7.5 mg, 10 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Upadacitinib",
        "description": "Selective Janus kinase 1 (JAK1) inhibitor; substance code ABT-494."
      },
      {
        "name": "Methotrexate",
        "description": "Antifolate antineoplastic and antirheumatic drug."
      }
    ],
    "administrations": [
      {
        "name": "Upadacitinib 15 mg QD",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Up to 260 weeks"
      },
      {
        "name": "Upadacitinib 30 mg QD",
        "dose": "30 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Period 1 and Period 2 (until Amendment 5)"
      },
      {
        "name": "Methotrexate weekly",
        "dose": "7.5 mg to 25 mg",
        "frequency": "once weekly",
        "route": "Oral",
        "duration": "14 weeks (Period 1)"
      },
      {
        "name": "Upadacitinib 15 mg Open-Label",
        "dose": "15 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Starting with Amendment 5 for all subjects"
      }
    ],
    "devices": []
  }
}